Biotech companies must quickly
convert new leads into purified therapeutics for clinical trials
and ultimately for the market. A key goal of the pilot
process facility is to make GMP compliant material for testing
and demonstrate a process scale-up essential to manufacturing
plant design. With an ever-increasing range of biologics
(therapeutic proteins and fragment, peptides, viruses and viral
capsids, naked DNA, and polysaccharides) expressed by a number of
host cells (bacterial, yeast, mammalian, insect, and plant
cells), the industry needs a versatile, scalable solid liquid
separator to process drugs for clinical studies. Our centrifuges
can meet this criteria.
